Effect of Desmopressin on Platelet Function in CKD Patients on Antiplatelet Agent Who Need Emergent Temporary Catheter Insertion for Hemodialysis
Overview
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- University of Ulsan
- Enrollment
- 25
- Locations
- 1
- Primary Endpoint
- collagen-epinephrine closure time
Overview
Brief Summary
Prolonged Collagen/Epinephrine - closure time (CEPI-CT) indicates platelet dysfunction in CKD patients taking antiplatelet agent. The synthetic vasopressin derivative, Desmopressin (DDAVP) shortens the prolonged bleeding time and improves platelet dysfunction measured by in vitro closure time: CEPI-CT in uremic patients. Desmopressin also antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors, clopidogrel and aspirin. The investigators designed a prospective study to evaluate the effect of desmopressin on platelet function, as measured by in vitro collagen/epinephrine - closure time, in uremic patients who were taking antiplatelet drugs.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 20 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •adult uremic patients with one or more antiplatelet medication,
- •prolonged collagen/epinephrine (CEPI) closure time,
- •need for emergent hemodialysis and
- •subsequent catheter insertion
Exclusion Criteria
- •acute coronary syndrome,
- •hemophilia, and nephrogenic diabetes insipidus,
- •allergy against desmopressin
Arms & Interventions
Desmopressin
Twenty five patients with chronic kidney disease and who were taking antiplatelet agents and needed an emergent catheter insertion for hemodialysis
Intervention: Desmopressin administration (Drug)
Outcomes
Primary Outcomes
collagen-epinephrine closure time
Time Frame: 1 hour
In vitro closure time (CT), measured using a platelet function analyzer (PFA)-100, is a relatively new tool for investigation of primary hemostasis. This system has been shown to be efficacious in evaluating abnormalities of primary hemostasis.
Secondary Outcomes
- Bleeding after procedure(1-4 hr after procedure)
Investigators
Soon Bae Kim, M.D., PhD.
Professor of Medicine
University of Ulsan